Navidea Biopharmaceuticals, Inc.
Hedge Funds Holdings
Last updated:
Navidea Biopharmaceuticals, Inc.‘s stocks are currently a part of 14 hedge funds’ portfolios, which represents 6.77% of the total amount of its stocks outstanding. This makes up a total of 577.09K shares of Navidea Biopharmaceuticals, Inc.. Compared to the previous quarter, the number fell by -64.67% or -1.05M shares fewer. As for the holding position changes, 21.43% (3) of current hedge fund investors increased the number of shares held, 28.57% (4) of current holders sold a part of the shares held, and 14.29% (2) closed the holdings completely. 2 hedge funds are new holders of Navidea Biopharmaceuticals, Inc. stock in Q1 2023, it is 14.29% of total holders.
Hedge funds holding Navidea Biopharmaceuticals (Q2 2018 – Q1 2023)
| Q2 2018 | 48 |
|---|---|
| Q3 2018 | 49 |
| Q4 2018 | 49 |
| Q1 2019 | 41 |
| Q2 2019 | 21 |
| Q3 2019 | 23 |
| Q4 2019 | 19 |
| Q1 2020 | 21 |
| Q2 2020 | 33 |
| Q3 2020 | 32 |
| Q4 2020 | 29 |
| Q1 2021 | 28 |
| Q2 2021 | 24 |
| Q3 2021 | 26 |
| Q4 2021 | 25 |
| Q1 2022 | 17 |
| Q2 2022 | 18 |
| Q3 2022 | 17 |
| Q4 2022 | 26 |
| Q1 2023 | 14 |
Hedge funds changes in Navidea Biopharmaceuticals positions (Q2 2018 – Q1 2023)
| Q2 2018 | 4 | 6 | 8 | 6 | 24 |
|---|---|---|---|---|---|
| Q3 2018 | 4 | 7 | 5 | 3 | 30 |
| Q4 2018 | 8 | 6 | 7 | 8 | 20 |
| Q1 2019 | 5 | 9 | 3 | 13 | 11 |
| Q2 2019 | 21 | 0 | 0 | 40 | -40 |
| Q3 2019 | 5 | 6 | 4 | 4 | 4 |
| Q4 2019 | 2 | 7 | 0 | 6 | 4 |
| Q1 2020 | 5 | 2 | 3 | 2 | 9 |
| Q2 2020 | 14 | 10 | 3 | 2 | 4 |
| Q3 2020 | 4 | 9 | 9 | 5 | 5 |
| Q4 2020 | 2 | 6 | 11 | 4 | 6 |
| Q1 2021 | 2 | 12 | 4 | 3 | 7 |
| Q2 2021 | 2 | 8 | 5 | 6 | 3 |
| Q3 2021 | 3 | 3 | 7 | 1 | 12 |
| Q4 2021 | 4 | 6 | 5 | 5 | 5 |
| Q1 2022 | 0 | 1 | 9 | 8 | -1 |
| Q2 2022 | 3 | 4 | 4 | 2 | 5 |
| Q3 2022 | 3 | 3 | 4 | 4 | 3 |
| Q4 2022 | 12 | 4 | 5 | 3 | 2 |
| Q1 2023 | 2 | 3 | 4 | 2 | 3 |
Hedge funds changes in Navidea Biopharmaceuticals stock options (Q2 2018 – Q1 2023)
| Q2 2018 | 0 | 0 |
|---|---|---|
| Q3 2018 | 0 | 0 |
| Q4 2018 | 0 | 0 |
| Q1 2019 | 1,000 | 0 |
| Q2 2019 | 0 | 14,000 |
| Q3 2019 | 14,000 | 47,000 |
| Q4 2019 | 142,000 | 114,000 |
| Q1 2020 | 60,000 | 16,000 |
| Q2 2020 | 285,000 | 161,000 |
| Q3 2020 | 397,000 | 372,000 |
| Q4 2020 | 351,000 | 377,000 |
| Q1 2021 | 369,000 | 390,000 |
| Q2 2021 | 385,000 | 566,000 |
| Q3 2021 | 250,000 | 619,000 |
| Q4 2021 | 96,000 | 379,000 |
| Q1 2022 | 60,000 | 270,000 |
| Q2 2022 | 39,000 | 233,000 |
| Q3 2022 | 14,000 | 52,000 |
| Q4 2022 | 3,121 | 4,042 |
| Q1 2023 | 0 | 0 |